Mikhail Blagoskonny is a researcher who has specialized in oncology. Oncology is the study of cancer and all that pertains to it. He studied in St. Petersburg, at the first Pavlov University taking an internal medicine at master’s level and later got a Ph.D. in experimental medicine and cardiology. He began his work, in 2002, as an associate professor of medicine at the New York medical college. He would later accept a job offer as a senior research scientist at the Ordway research institute in Albany. He only left the Ordway Institute much later in 2009. This occurred after he was given a position at the Rosewell Park Cancer Institute as a professor of oncology. A position he continues to hold till present. Mikhail has published many scholarly articles and as such has found himself as the editor-in-chief of publications platforms such as Aging, Cell Cycle, and Oncotarget. He is also a member of the Cell Death & Differentiation editorial board. Mr.Blagoskonny also doubles in philanthropy by championing for the availability of proper treatment despite an individual’s liquidity and more information click here.
As a professor of oncology, Mr. Blagoskonny has put a lot of effort into the medical research field primarily focusing on cancer and how it’s connected to aging. He is particularly interested in the connection between cancerous conditions and why they mostly occur among older people who are above a certain age. These research areas, touching on cancer and its relationship to aging, have attracted the attention of many scholarly individuals within the medical sphere and learn more about Mikhail.
Mr. Blagoskonny postulates that there is a role played by TOR signaling in aging and cancer. He believes that rapamycin has anti-aging capabilities and proposes it to be used as a life extension tool. He is researching the possibility of rapamycin slowing down the aging process besides tackling cancer cells in cancer patients. He argues against a paper written by Nef, Erhinger, and others who claim that rapamycin can increase a life span but not affect aging. If by increasing life span, rapamycin reduces the risk of death then in retrospect it slows down aging by pushing it further away.
Cancer therapy is very painful and is usually very costly. For a long time, the less able have had to succumb to cancer due to lack of adequate finances for treatment. Mr. Blagoskonny intends to find a method with which cancer can be eradicated, from a sick patient, in a way that will be both inexpensive and rather painless compared to most if not all present day methods. His research aims at finding an alternative that will eradicate cancer cells from the body while preserving healthy cells, unlike the current methods where all cells adversely affected during therapy. These healthy cells are especially necessary when recovering after long durations of cancer treatment.
Mr. Blagoskonny as a leader and professor has inspired many of his students and his peers who have picked up where he leaves. He hopes that more will do the same to help in achieving the dream where cancer therapy will be an easily available treatment and not the luxurious service it has been made out to be and Mikhail’s lacrosse camp.